InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: alexander77 post# 300121

Friday, 08/14/2020 5:24:38 AM

Friday, August 14, 2020 5:24:38 AM

Post# of 690935
dcvax-l got a positive note in a very negative, recent article "While the interim analysis from the trial showed an eight-month OS survival benefit for the addition of DCVax-L to SoC, key stakeholders in the field have indicated potential patient selection bias (7,14)" The KOL comments she is referring to are posted in my previous post. You can see not all KOLs agree with what she is saving.
https://www.cellandgene.com/doc/immunotherapy-for-glioblastoma-a-path-forward-0001
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News